TRIAL DETAIL

Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)

Drug:
Trial Name:
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Not yet recruiting
Phase:
2
Start Date 11/01/2021
Age of Trial (yrs) .9
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor + MEK inhibitor
Strategy:
Block KIT + Block related tumor signal paths
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
DCC-2618-01-008
Sponsor:
Deciphera Pharmaceuticals LLC
Patient Contact:
Study Director 785-830-2100 clinicaltrials@deciphera.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
Exclusion Criteria:

Received prior anticancer therapy within 14 days or 5× the half-life whichever is longer) prior to the first dose.
Ongoing or prior participation in the DCC-2618-03-002 study.
Prior therapy with ripretinib.
Prior therapy with MEK inhibitor.
History of certain ocular disorders.
History of clinically significant hepatobiliary disease.
Known active central nervous system metastases.
History or presence of clinically relevant cardiovascular abnormalities.
Systemic arterial or venous thrombotic or embolic events within 6 months of first dose.
History of acute or chronic pancreatitis
History of chronic inflammatory bowel disease or Crohn's disease requiring intervention within 12 months of first dose.

Gastrointestinal abnormalities including but not limited to:
inability to take oral medication,
malabsorption syndromes

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
1475 Northwest 12th Ave
Miami
FL
33136
USA
1275 York Ave
New York
NY
10065
USA
1505 Holcombe Blvd.
Houston
TX
77030
USA
610 University Ave
Toronto
ON
M5G 2M9
Canada
Hufelandstr. 55
Essen
45122
Germany
Barcelona
08035
Spain